HR 7902119th CongressIn Committee

To provide that the approved application under the Federal Food, Drug, and Cosmetic Act for the drug mifepristone for the purpose of the termination of intrauterine pregnancy is deemed to have been withdrawn, to establish a Federal tort for harm to women caused by chemical abortion drugs, and for other purposes.

Standard Summary
Balanced plain-English summary

This bill would withdraw FDA approval for mifepristone when used to terminate intrauterine pregnancy, treat related interstate commerce as a violation, create a federal private right of action against manufacturers for harm, and require misbranding labeling.

Key Points

  • 1Deems FDA approval of mifepristone for pregnancy termination withdrawn 14 days after enactment
  • 2Treats introduction of the withdrawn drug into interstate commerce as a violation
  • 3Creates federal tort liability and a private right of action against manufacturers for bodily or mental harm
  • 4Allows compensatory damages, punitive damages, attorney fees, and costs
  • 5Does not preempt other state-law remedies

Impact Areas

Women seeking abortion careMifepristone manufacturersHealthcare providers and pharmaciesFDA and federal courtsState regulators
Generated by deepseek/deepseek-v4.1-flash-1017Nov 18, 2026